GIST pipeline
Trial arms side by side.
One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.
ClassNone selected
No arms selected. Choose a drug, an arm, or a preset.
Each arm uses its closest stored timepoint inside the window.
value
Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.
No selected arm has this endpoint inside the time window.
Show as table
| Arm | Trial | Phase | Population | n | Comparator | Timepoint | Estimand | Assessor | Value |
|---|
Not shown
Every selected arm is drawn.
26 of 32 arms with a reported figure. Choose arms to narrow the chart.
| Arm | Reported safety |
|---|---|
| Imatinib 400 mg | n/r |
| Imatinib 800 mg | n/r |
| Imatinib 400 mg | n/r |
| Imatinib 600 mg | n/r |
| Imatinib 400 mg | n/r |
| Imatinib 400 mg | n/r |
| Sunitinib 50 mg | n/r |
| Sunitinib placebo | n/r |
| Regorafenib 160 mg | n/r |
| Regorafenib placebo | n/r |
| Ripretinib 150 mg | n/r |
| Ripretinib placebo | n/r |
| Ripretinib 150 mg | grade 3 or 4 treatment-emergent adverse events: 41.3%, primary analysis |
| Ripretinib 50 mg | grade 3 or 4 treatment-emergent adverse events: 65.6%, primary analysis |
| Avapritinib 300 or 400 mg | n/r |
| Avapritinib 300 or 400 mg | n/r |
| Avapritinib 300 or 400 mg | intracranial hemorrhage: 1.1%, label pooled GIST |
| Avapritinib 300 mg | n/r |
| Avapritinib 160 mg | n/r |
| Bezuclastinib + Sunitinib 600 mg + 37.5 mg | grade 3 or higher ALT/AST increased: 10.8%, data cutoff 09.30.2025discontinued for treatment-related adverse events: 7.4%, data cutoff 09.30.2025 |
| Bezuclastinib + Sunitinib 37.5 mg | grade 3 or higher ALT/AST increased: 1.4%, data cutoff 09.30.2025discontinued for treatment-related adverse events: 3.8%, data cutoff 09.30.2025 |
| Velzatinib (IDRX-42, GSK6042981) 300 mg | n/r |
| Velzatinib (IDRX-42, GSK6042981) 300 mg | n/r |
| Olverembatinib (HQP1351) 30 to 50 mg | n/r |
| NB003 not stated in source | n/r |
| NB003 not stated in source | n/r |
A count stays a count. This page does not turn a count into a percent.
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.